Incyte Corporation announced positive results from the Phase 3 STOP-HS trials of povorcitinib for treating hidradenitis suppurativa, a painful skin condition. The studies showed efficacy and safety with a significant reduction in abscesses and nodules.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing